{"id":"comparator-varivax","safety":{"commonSideEffects":[{"rate":"19-35","effect":"Injection site reactions (erythema, swelling, pain)"},{"rate":"10-15","effect":"Fever"},{"rate":"3-5","effect":"Varicella-like rash (vaccine strain)"},{"rate":"1-2","effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Varivax contains a weakened form of the varicella-zoster virus (VZV) that replicates in the body at low levels, triggering both cellular and humoral immune responses without causing disease. This vaccination induces protective antibodies and cell-mediated immunity against VZV, preventing or significantly reducing the severity of chickenpox infection upon natural exposure.","oneSentence":"Varivax is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:20.105Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of varicella (chickenpox) in children and adults"}]},"trialDetails":[{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT03604406","phase":"PHASE2","title":"The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kevin Winthrop","startDate":"2014-05-08","conditions":"Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT03893448","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-19","conditions":"Pneumococcal Infections, Pneumococcal Vaccines","enrollment":1720},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT05130398","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2021-04-09","conditions":"Ebola Virus Disease","enrollment":120},{"nctId":"NCT03375502","phase":"PHASE2, PHASE3","title":"A Study of MG1111 in Healthy Children","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2016-11-26","conditions":"Healthy Children","enrollment":814},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT00326183","phase":"PHASE4","title":"Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-26","conditions":"Hepatitis A, Measles, Mumps","enrollment":1800},{"nctId":"NCT00969436","phase":"PHASE3","title":"Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-09","conditions":"Varicella, Rubella, Mumps","enrollment":450},{"nctId":"NCT00312858","phase":"PHASE4","title":"Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-04","conditions":"Hepatitis A Virus","enrollment":653},{"nctId":"NCT00550745","phase":"PHASE4","title":"ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":"Herpes Zoster","enrollment":11999},{"nctId":"NCT00822237","phase":"PHASE3","title":"Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Varicella","enrollment":598},{"nctId":"NCT00546819","phase":"PHASE2","title":"ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Herpes Zoster","enrollment":309},{"nctId":"NCT00535730","phase":"PHASE3","title":"ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Herpes Zoster, Pneumococcal Infection","enrollment":473},{"nctId":"NCT00534248","phase":"PHASE3","title":"Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Shingles","enrollment":22439},{"nctId":"NCT00109343","phase":"PHASE3","title":"V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-03","conditions":"Measles, Mumps, Rubella","enrollment":1027},{"nctId":"NCT00109122","phase":"PHASE2","title":"Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-11","conditions":"Shingles","enrollment":180},{"nctId":"NCT00985153","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2000-03","conditions":"Measles, Mumps, Rubella","enrollment":3927},{"nctId":"NCT00092391","phase":"PHASE3","title":"A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1999-02","conditions":"Measles, Mumps, Rubella","enrollment":1997},{"nctId":"NCT00975507","phase":"PHASE3","title":"ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-03","conditions":"Measles, Mumps, Rubella","enrollment":480},{"nctId":"NCT00886613","phase":"PHASE1","title":"A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":"Herpes Zoster","enrollment":120},{"nctId":"NCT00231816","phase":"PHASE3","title":"A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Herpes Zoster","enrollment":763},{"nctId":"NCT00984295","phase":"PHASE3","title":"Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2000-06","conditions":"Measles, Mumps, Rubella","enrollment":1913},{"nctId":"NCT00985166","phase":"PHASE3","title":"A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2000-08","conditions":"Measles, Mumps, Rubella","enrollment":801},{"nctId":"NCT00986232","phase":"PHASE2","title":"ProQuad Dose Selection Study (V221-011)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1999-04","conditions":"Measles, Mumps, Rubella","enrollment":1551},{"nctId":"NCT00322231","phase":"PHASE3","title":"A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Herpes Zoster","enrollment":101},{"nctId":"NCT00130793","phase":"PHASE3","title":"A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Herpes Zoster","enrollment":368}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: Varivax","genericName":"Comparator: Varivax","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Varivax is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox infection. Used for Prevention of varicella (chickenpox) in children and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}